Sign Out
UserName
Profession Email
Profession Email
|
Contraindications
Hypersensitivity. Lactation. Concomitant use with yellow fever vaccine.
|
|
Special Precautions
Patient with hypertension, diabetes, dehydration, CV disorders. Patient who have received radiation therapy. Renal impairment. Monitoring Parameters Monitor CBC with differential and platelets prior to each cycle, on days 8 and 15, and as necessary; renal functions (e.g. serum creatinine, CrCl, and BUN); total bilirubin, ALT, AST. Assess for signs and symptoms of mucositis and diarrhoea, pulmonary toxicity, dermatologic reactions, and radiation recall.
|
|
Adverse Reactions
Significant: Hypersensitivity, severe myelosuppression (e.g. anaemia, neutropenia, thrombocytopenia, pancytopenia), gastrointestinal toxicity, radiation recall, dehydration, nephrogenic diabetes insipidus, renal tubular necrosis.
Eye disorders: Conjunctivitis.
Gastrointestinal disorders: Stomatitis, pharyngitis, nausea, vomiting, diarrhoea, anorexia, constipation, dyspepsia.
General disorders and administration site conditions: Fever, fatigue.
Investigations: Raised creatinine, tranasminases; decreased CrCl.
Nervous system disorders: Neuropathy, taste disturbance.
Skin and subcutaneous tissue disorders: Rash, desquamation, alopecia, pruritus.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis, nephrotoxicity, pulmonary toxicity. |
|
Drug Interactions
Increased plasma concentrations with NSAIDs (e.g. ibuprofen) and aspirin. Delayed excretion with nephrotoxic drugs (e.g. aminoglycosides, loop diuretics, platinum compounds, ciclosporin), probenecid, and penicillin.
|
|
CIMS Class
|
|
ATC Classification
L01BA04 - pemetrexed ; Belongs to the class of antimetabolites, folic acid analogues. Used in the treatment of cancer.
|
